{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:33:29Z","timestamp":1793406809407,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T00:00:00Z","timestamp":1606521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.jhep.2020.11.045","type":"journal-article","created":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T11:34:42Z","timestamp":1606908882000},"page":"1188-1199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":149,"title":["Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease"],"prefix":"10.1016","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7290-0484","authenticated-orcid":false,"given":"Zoe","family":"Boyer-Diaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2911-7870","authenticated-orcid":false,"given":"Peio","family":"Aristu-Zabalza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Andr\u00e9s-Rozas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00ed","family":"Ortega-Ribera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2364-6675","authenticated-orcid":false,"given":"Anabel","family":"Fern\u00e1ndez-Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Broqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Junien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Wettstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3414-0055","authenticated-orcid":false,"given":"Jaime","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7736-4089","authenticated-orcid":false,"given":"Jordi","family":"Gracia-Sancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2020.11.045_bib1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nri3623","article-title":"Liver fibrosis and repair: immune regulation of wound healing in a solid organ","volume":"14","author":"Pellicoro","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jhep.2020.11.045_bib2","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1016\/j.jhep.2015.01.003","article-title":"Evolution in the understanding of the pathophysiological basis of portal hypertension: how changes in paradigm are leading to successful new treatments","volume":"62","author":"Bosch","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.11.045_bib3","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41575-018-0097-3","article-title":"Hepatic microcirculation and mechanisms of portal hypertension","volume":"16","author":"Gracia-Sancho","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2020.11.045_bib4","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(14)60121-5","article-title":"Liver cirrhosis","volume":"383","author":"Tsochatzis","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2020.11.045_bib5","doi-asserted-by":"crossref","first-page":"107626","DOI":"10.1016\/j.pharmthera.2020.107626","article-title":"Novel therapeutics for portal hypertension and fibrosis in chronic liver disease","volume":"215","author":"Guix\u00e9-Muntet","year":"2020","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jhep.2020.11.045_bib6","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.biochi.2016.11.009","article-title":"PPARs and nonalcoholic fatty liver disease","volume":"136","author":"Liss","year":"2017","journal-title":"Biochimie"},{"key":"10.1016\/j.jhep.2020.11.045_bib7","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.plipres.2005.12.002","article-title":"From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions","volume":"45","author":"Feige","year":"2006","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.jhep.2020.11.045_bib8","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41575-020-00366-5","article-title":"Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors","volume":"18","author":"Francque","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2020.11.045_bib9","doi-asserted-by":"crossref","first-page":"E1369","DOI":"10.1073\/pnas.1202464109","article-title":"Protection from liver fibrosis by a peroxisome proliferator-activated receptor \u03b4 agonist","volume":"109","author":"Iwaisako","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jhep.2020.11.045_bib10","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jhep.2011.12.008","article-title":"PPAR\u03b1 activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats","volume":"56","author":"Rodr\u00edguez-Vilarrupla","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.11.045_bib11","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/hep.26461","article-title":"Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha\/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"58","author":"Staels","year":"2013","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.jhep.2020.11.045_bib12","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/hep4.1072","article-title":"The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice","volume":"1","author":"Haczeyni","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2020.11.045_bib13","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.ajpath.2018.03.018","article-title":"Beneficial effects of the peroxisome proliferator-activated receptor \u03b1\/\u03b3 agonist aleglitazar on progressive hepatic and splanchnic abnormalities in cirrhotic rats with portal hypertension","volume":"188","author":"Tsai","year":"2018","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhep.2020.11.045_bib14","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/liv.13634","article-title":"Dual PPAR\u03b1\/\u03b3 agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models","volume":"38","author":"Jain","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2020.11.045_bib15","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.biopha.2018.12.130","article-title":"Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis \u2013 effects of a peroxisome proliferator-activated receptor gamma (PPAR-\u03b3) agonist and a glucagon-like peptide-1 analogue","volume":"111","author":"Daniels","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jhep.2020.11.045_bib16","doi-asserted-by":"crossref","first-page":"757803","DOI":"10.1155\/2012\/757803","article-title":"PPARs in liver diseases and cancer: epigenetic regulation by microRNAs","volume":"2012","author":"Peyrou","year":"2012","journal-title":"PPAR Res"},{"key":"10.1016\/j.jhep.2020.11.045_bib17","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.2174\/09298673113209990136","article-title":"Hepatic PPARs: their role in liver physiology, fibrosis and treatment","volume":"20","author":"Zardi","year":"2013","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jhep.2020.11.045_bib18","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/hep4.1057","article-title":"The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis","volume":"1","author":"Wettstein","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2020.11.045_bib19","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1021\/acs.jmedchem.7b01285","article-title":"Design, synthesis, and evaluation of a novel series of indole sulfonamide peroxisome proliferator activated receptor (PPAR) \u03b1\/\u03b3\/\u03b4 triple activators: discovery of lanifibranor, a new antifibrotic clinical candidate","volume":"61","author":"Boubia","year":"2018","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jhep.2020.11.045_bib20","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jhep.2020.04.025","article-title":"Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages","volume":"73","author":"Lefere","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.11.045_bib21","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1053\/j.gastro.2018.07.022","article-title":"Simvastatin prevents progression of acute on chronic liver failure in rats with cirrhosis and portal hypertension","volume":"155","author":"Tripathi","year":"2018","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.jhep.2020.11.045_bib22","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.3390\/nu11102358","article-title":"A\u00a0nutraceutical rich in docosahexaenoic acid improves portal hypertension in a preclinical model of advanced chronic liver disease","volume":"11","author":"Boyer-Diaz","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.jhep.2020.11.045_bib23","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jhep.2020.04.011","article-title":"Animal models for liver disease \u2013 a practical approach for translational research","volume":"73","author":"Nevzorova","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.11.045_bib24","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1002\/bit.26776","article-title":"Resemblance of the human liver sinusoid in a fluidic device with biomedical and pharmaceutical applications","volume":"115","author":"Ortega-Ribera","year":"2018","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.jhep.2020.11.045_bib25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.biochi.2016.12.019","article-title":"The role and regulation of the peroxisome proliferator activated receptor alpha in human liver","volume":"136","author":"Kersten","year":"2017","journal-title":"Biochimie"},{"key":"10.1016\/j.jhep.2020.11.045_bib26","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00005-008-0037-y","article-title":"Structure and physiological functions of the human peroxisome proliferator-activated receptor \u03b3","volume":"56","author":"Zieleniak","year":"2008","journal-title":"Arch Immunol Ther Exp"},{"key":"10.1016\/j.jhep.2020.11.045_bib27","first-page":"9A","article-title":"The panPPAR agonist lanifibranor induces both resolution of NASH and regression of fibrosis after 24 weeks of treatment in non-cirrhotic nash: results of the NATIVE phase 2b trial","volume":"72","author":"Francque","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.11.045_bib28","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jhep.2008.01.021","article-title":"The management of portal hypertension: rational basis, available treatments and future options","volume":"48","author":"Bosch","year":"2008","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.11.045_bib29","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","article-title":"\u03b2 blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial","volume":"393","author":"Villanueva","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2020.11.045_bib30","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.5858\/2000-124-1599-ROHC","article-title":"Regression of human cirrhosis: morphologic features and the genesis of incomplete septal cirrhosis","volume":"124","author":"Wanless","year":"2000","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"10.1016\/j.jhep.2020.11.045_bib31","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1053\/gast.2000.9365","article-title":"Ligands of peroxisome proliferator-activated receptor \u03b3 modulate profibrogenic and proinflammatory actions in hepatic stellate cells","volume":"119","author":"Marra","year":"2000","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jhep.2020.11.045_bib32","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cellsig.2011.11.008","article-title":"Peroxisome proliferator-activated receptor-\u03b3 cross-regulation of signaling events implicated in liver fibrogenesis","volume":"24","author":"Zhang","year":"2012","journal-title":"Cell Signal"},{"key":"10.1016\/j.jhep.2020.11.045_bib33","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/hep.510280405","article-title":"Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats","volume":"28","author":"Gupta","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.11.045_bib34","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/MCG.0b013e3181572357","article-title":"Vascular deterioration in cirrhosis: the big picture","volume":"41","author":"Bosch","year":"2007","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2020.11.045_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/s41575-020-00411-3","article-title":"Role of liver sinusoidal endothelial cells in liver diseases","author":"Gracia-Sancho","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2020.11.045_bib36","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jhep.2012.08.026","article-title":"The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins","volume":"58","author":"Marrone","year":"2013","journal-title":"J\u00a0Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827820338320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827820338320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T10:50:09Z","timestamp":1726051809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827820338320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0168827820338320"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2020.11.045","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2020.11.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Association for the Study of the Liver. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}